Petros pharmaceuticals reports positive results in an initial cohort two-arm self-selection (phase 2-equivalent) study for stendra(r) (avanafil) as it pursues otc status

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an otc setting (please see important safety information below) new york, ny / accesswire / april 2, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces positive results of an initial cohort of its self-selection study comparing the use of a drug facts label (dfl) alone to a dfl in combination with a web app (technology component).
PTPI Ratings Summary
PTPI Quant Ranking